Corvus Pharmaceuticals, Inc. (NasdaqGM: CRVS)
Health Care · Biotechnology · US
$14.73
+1.17% today · +167.8% 1Y
Corvus Pharmaceuticals, Inc. (NasdaqGM: CRVS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.24B and employs 37 people.
Over the last twelve months the share price has gained 167.8%, trading between 5.28 and 26.95.
Tweenvest scores Corvus Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
CRVS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.24B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.62
- Dividend yield
- —
- Beta (5Y)
- 0.87
- 52-week high
- $26.95
- 52-week low
- $5.28
- Avg volume (3M)
- —
- Shares outstanding
- 84.12M
- Employees
- 37
- Next earnings
- —
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
- ISIN
- US2210151005
- Founded
- 2014
- Listed since
- Mar 23, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.